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Abstract
Herceptin (trastuzumab) is used in patients with breast cancer who have HER2 (ErbB2)–positive tumours. However, its
mechanisms of action and how acquired resistance to Herceptin occurs are still poorly understood. It was previously
thought that the anti-HER2 monoclonal antibody Herceptin inhibits HER2 signalling, but recent studies have shown that
Herceptin does not decrease HER2 phosphorylation. Its failure to abolish HER2 phosphorylation may be a key to why
acquired resistance inevitably occurs for all responders if Herceptin is given as monotherapy. To date, no studies have
explained why Herceptin does not abolish HER2 phosphorylation. The objective of this study was to investigate why
Herceptin did not decrease HER2 phosphorylation despite being an anti-HER2 monoclonal antibody. We also investigated
the effects of acute and chronic Herceptin treatment on HER3 and PKB phosphorylation in HER2-positive breast cancer cells.
Using both Fo ¨rster resonance energy transfer (FRET) methodology and conventional Western blot, we have found the
molecular mechanisms whereby Herceptin fails to abolish HER2 phosphorylation. HER2 phosphorylation is maintained by
ligand-mediated activation of EGFR, HER3, and HER4 receptors, resulting in their dimerisation with HER2. The release of HER
ligands was mediated by ADAM17 through a PKB negative feedback loop. The feedback loop was activated because of the
inhibition of PKB by Herceptin treatment since up-regulation of HER ligands and ADAM17 also occurred when PKB
phosphorylation was inhibited by a PKB inhibitor (Akt inhibitor VIII, Akti-1/2). The combination of Herceptin with ADAM17
inhibitors or the panHER inhibitor JNJ-26483327 was able to abrogate the feedback loop and decrease HER2
phosphorylation. Furthermore, the combination of Herceptin with JNJ-26483327 was synergistic in tumour inhibition in
a BT474 xenograft model. We have determined that a PKB negative feedback loop links ADAM17 and HER ligands in
maintaining HER2 phosphorylation during Herceptin treatment. The activation of other HER receptors via ADAM17 may
mediate acquired resistance to Herceptin in HER2-overexpressing breast cancer. This finding offers treatment opportunities
for overcoming resistance in these patients. We propose that Herceptin should be combined with a panHER inhibitor or an
ADAM inhibitor to overcome the acquired drug resistance for patients with HER2-positive breast cancer. Our results may
also have implications for resistance to other therapies targeting HER receptors.
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Introduction
Dysregulation of human epidermal growth factor (HER/ErbB)
receptors is implicated in various epithelial cancers [1]. The four
HER receptors are capable of dimerising with each other (homo-
dimerisation) or with different HER receptors (heterodimerisation)
upon ligand binding [2]. The homo- or heterodimerisation of the
receptors results in the activation of the intrinsic tyrosine kinase
domain and autophosphorylation of specific tyrosine residues in the
C-terminal tail [2]. The ligand-induced HER receptor dimerisation
follows a strict hierarchy, and HER2 has been shown to be the
preferred dimerisation partner [3]. The crystal structure explains why
HER2 is ligandless, since its extracellular domain is always in the
‘‘open’’ conformation, with the projection of domain II ready for
dimerisation even when monomeric [4]. This fixed ‘‘open’’
conformation of HER2 in the absence of ligand binding (mimicking
the ligand-bound form in the EGFR structure) may account for why
it is the preferred dimerisation partner [3].
PLoS Biology | www.plosbiology.org 1 December 2010 | Volume 8 | Issue 12 | e1000563Herceptin (trastuzumab) is a humanised mouse monoclonal
antibody 4D5 and binds to the juxtamembrane region of HER2 of
domain IV [4]. However, the precise mechanisms of its action and
its acquired resistance are still poorly understood. Around 15%–
20% of patients with breast cancer have HER2-positive tumours,
and the amplification or overexpression of HER2 has been shown
to be a significant predictor for both overall survival and time to
relapse in these patients [5]. Herceptin has been shown to induce
tumour regression in about a third of patients with metastatic
HER2-positive breast cancer, but the response is rarely sustained if
Herceptin is given as a single agent [6]. Therefore, understanding
the mechanisms of its acquired resistance is of paramount
importance.
The current proposed primary mechanisms of action for
Herceptin include HER2 receptor down-regulation and inhibition
of aberrant receptor tyrosine kinase activity [7,8]. There is strong
evidence of an immune-mediated mechanism in which the
interaction of Herceptin’s human Fc region with immune effector
cells results in the stimulation of natural killer cells and activation
of antibody-dependent cellular cytotoxicity [9,10]. Other proposed
mechanisms of Herceptin’s action include inhibition of basal and
activated HER2 ectodomain cleavage in breast cancer cells [11],
the induction of G1 arrest and cyclin-dependent kinase inhibitor
p27
Kip1 levels [12], or activation of PTEN [13].
Although Herceptin was developed to target the HER2
receptor, recent studies have shown that Herceptin does not
decrease HER2 phosphorylation [14,15]. Its failure to abolish
HER2 phosphorylation may be a key to why acquired resistance
inevitably occurs for all responders if Herceptin is given as
monotherapy. To date, no studies have explained why Herceptin
does not abolish HER2 phosphorylation. The objective of our
study was to investigate why Herceptin did not decrease HER2
phosphorylation despite being an anti-HER2 monoclonal anti-
body. We also investigated the effects of acute and chronic
Herceptin treatment on HER3 and PKB phosphorylation in
HER2-positive breast cancer cells.
We showed that HER2 phosphorylation was maintained by the
activation of other HER receptors during Herceptin treatment
through an ADAM17-mediated ligand release. Although Herceptin
initially decreased HER3 phosphorylation, reactivation of HER3
occurred in prolonged Herceptin treatment through a PKB negative
feedback loop. The reactivation of HER3 and failure of Herceptin to
abolish HER2 phosphorylation may be responsible for acquired
resistance to Herceptin in HER2-overexpressing breast cancer.
Results
Herceptin Does Not Abolish HER2 Phosphorylation in
HER2-Overexpressing Breast Cancer Cells
We investigated how binding of HER2 receptors by the anti-
HER2 monoclonal antibody Herceptin affects HER2 receptors.
Although Herceptin was initially thought to inhibit aberrant
HER2 receptor tyrosine kinase activity, recent studies have shown
that Herceptin does not decrease HER2 phosphorylation [14,15].
However, the mechanisms of why Herceptin does not inhibit
HER2 phosphorylation have not been elucidated. Furthermore,
studies that have investigated the effect of Herceptin on HER2
phosphorylation have typically been based on classical Western
blot analysis, which cannot detect phosphorylation status in
individual cells. We proceeded to monitor the effect of Herceptin
on HER2 phosphorylation in HER2-overexpressing cells using
classical biochemical methods in combination with an established
Fo ¨rster resonance energy transfer (FRET) methodology that can
assess HER2 phosphorylation in individual cells [16].
Using the classical biochemical methods, we confirmed that
Herceptin down-regulated HER2 receptors in sensitive SKBR3
cells after 10 d of treatment (Figure 1A). We then assessed the
effect of Herceptin on HER2 phosphorylation. Herceptin did not
decrease nor abolish HER2 phosphorylation (Figure 1A). Para-
doxically, it increased HER2 phosphorylation in SKBR3 cells.
However, despite an increase in HER2 phosphorylation, there was
a decrease in cell viability in SKBR3 cells after 10 d of Herceptin
treatment compared to untreated cells (p=0.02) (Figure 1B). Since
a Western blot is unable to assess HER2 phosphorylation in
individual cells or assess heterogeneity between cells, we proceeded
to use FRET to assess HER2 phosphorylation in individual cells.
Using an established method to assess HER2 phosphorylation
by FRET [16,17], we conjugated an anti-HER2 antibody to a
Cy3b fluorophore (HER2-Cy3b) and an anti-phospho-HER2
antibody to Cy5 (pHER2-Cy5) to assess HER2 phosphorylation in
fixed SKBR3 cells with or without 40 mg/ml Herceptin (see
Materials and Methods). The median donor lifetime of Cy3b was
2.15 ns (Figure 1C). HER2 phosphorylation would bring the
donor and acceptor fluorophores into close proximity, resulting in
a decrease of donor lifetime. We first monitored the basal
phosphorylation in SKBR3 cells (without Herceptin treatment)
and found a decrease in the average lifetime of HER2-Cy3b when
pHER2-Cy5 was present (from 2.15 ns to 1.4 ns) (Figure 1C).
Following Herceptin treatment, there was considerable heteroge-
neity between the cells, with suppression of HER2 phosphoryla-
tion in a few cells, although the phosphorylation of HER2 was
maintained in the majority of cells (Figure 1C). After 10 d of
Author Summary
HER2 (ErbB2) is a surface protein and member of the
epidermal growth factor receptor (EGFR) family that is
overexpressed in approximately one-fifth of breast can-
cers. HER2-positive breast tumours tend to be very
aggressive, and patients with this type of tumour have a
poor prognosis. A therapeutic monoclonal antibody called
trastuzumab (Herceptin) has been designed to block HER2
signalling and is used as a treatment for patients with
HER2-positive breast cancer. However, recent studies have
shown that Herceptin does not decrease HER2 activation.
This may be why patients invariably develop resistance if
treated with Herceptin monotherapy. To date, no study
has explained why Herceptin cannot abolish HER2
signalling despite being an anti-HER2 monoclonal anti-
body. We have found that Herceptin switches on a
feedback loop that increases the production of the
ADAM17 protein, a protease that in turn releases the
growth factors that activate HER (ErbB) receptors. These
growth factors activate HER2 and also the other members
of the HER receptor family—EGFR, HER3 and HER4—in
such a way as to maintain HER2 activation and cell survival
in HER2-positive breast cancer cells. We have found that
when Herceptin is provided in combination with ADAM17
inhibitors, the feedback loop is abrogated in cells.
Furthermore, a pan-HER inhibitor that decreases the
activation of other HER receptors can also inhibit the
feedback loop and decrease HER2 activation when used in
combination with Herceptin. We further demonstrated
that the combination therapy of Herceptin with a pan-HER
inhibitor is more effective than Herceptin alone in an
animal model of breast cancer. We believe our results offer
treatment strategies that may help overcome acquired
Herceptin resistance in patients with HER2-positive breast
cancer.
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HER2 phosphorylation (Figure 1C), and this represented
approximately 50% of the cell number compared to untreated
cells (p=0.02) (Figure 1B). Herceptin has been shown to target
ALDH-positive stem cells in HER2-overexpressing breast cancer
cells [18,19]. We proceeded to show that after 6 d of Herceptin
treatment, there was a decreased proportion of cells that were
ALDH positive compared to untreated cells, correlated with a
decrease in HER2 receptors (Figure S1).
As control, the effect of Herceptin on HER2 phosphorylation in
the normal breast epithelial cell line MCF12F was also assessed.
Even though acute Herceptin treatment could not inhibit HER2
phosphorylation in SKBR3 cells, it was able to decrease HER2
phosphorylation (shown by increase of lifetime) in MCF12F cells
(Figure S2A). The inability of Herceptin to inhibit HER2
phosphorylation in SKBR3 cells was not due to the degradation
of Herceptin (Figure S2B).
Wealso observedsimilarresultsinanotherHER2-overexpressing
cell line, BT474 (Figure 1D). These cells were also sensitive to
Herceptin treatment after several days of treatment, with decreased
cell viability compared to control (Figure S3A, upper panel). As in
SKBR3 cells, acute Herceptin exposure did not decrease HER2
phosphorylation in these cells (Figure 1D). HER2 phosphorylation
increased in BT474 cells after 1 h of Herceptin treatment
(Figure 1D). After treating these cells with Herceptin for 8 mo
(with replacement of Herceptin every week), the cells became
resistant to 40 mg/ml Herceptin (Figure S3A, lower panel).
Herceptin was able to decrease but not eliminate ALDH-positive
stem cells in long-term Herceptin-treated BT474 cells compared to
untreated cells (Figure S3B). The decrease in ALDH-positive cells
correlated with down-regulation of HER2 receptors. However,
HER2 phosphorylation and cell viability remained in these resistant
cells treated for a prolonged period with Herceptin (Figure 1D).
The Effects of Acute Herceptin Treatment on HER3 and
PKB Phosphorylation
We found that the down-regulation of HER2 receptors was
detectable after 1 h of Herceptin treatment in BT474 cells, and
Figure 1. Herceptin down-regulates HER2 receptors and decreases HER3 phosphorylation, but it does not decrease HER2
phosphorylation. (A) SKBR3 cells were lysed for Western blot analysis after pre-treatment with 40 mg/ml Herceptin for a period of 4 h, 2 d, or 10 d.
Equal amounts of protein were loaded in each lane, and two SDS-PAGE gels were run. Membranes were blotted with appropriate antibodies for total
and phosphorylated HER2 and actin. (B) SKBR3 cells were grown in 24-well plates and left to grow for at least 24 h before being treated with 40 mg/
ml Herceptin for different durations, as illustrated. The viable cells were counted in a cell viability analyzer using trypan blue to stain the dead cells. (C)
SKBR3 cells were incubated with either donor alone (HER2-Cy3b) or donor and acceptor (HER2-Cy3b+pHER2-Cy5) to assess HER2 phosphorylation by
FRET after pre-treatment with 40 mg/ml Herceptin for different durations, as illustrated. (D) BT474 cells were lysed for Western blot analysis after pre-
treatment with 40 mg/ml Herceptin for a period of 1 h, 1 d, or 8 mo with replacement every week. Equal amounts of protein were loaded in each
lane. Membranes were blotted with antibodies for total and phosphorylated HER2 and actin. (E) BT474 cells were immunoprecipitated with an
antibody for cytoplasmic anti-HER2 (1:100). Following the immunoprecipitation the cell lysate was loaded on an SDS gel. The membrane was probed
with antibodies for total or phosphorylated HER2. (F) BT474 and SKBR3 cells were lysed after pre-treatment with 40 mg/ml Herceptin for 1 h. Equal
amounts were loaded on an SDS gel, and membranes were probed for phosphorylated HER3, phosphorylated PKB, and actin.
doi:10.1371/journal.pbio.1000563.g001
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(Figure 1E). Lee-Hoeflich et al. [20] showed that knockdown of
HER2 receptors but not EGFR caused a significant decrease of
HER3 phosphorylation in HER2-positive breast cell lines. We
investigated whether this occurred in our experiments. After 1 h of
Herceptin treatment in SKBR3 and BT474 cells, there was a
decrease in HER3 phosphorylation correlating with a down-
regulation of HER2 receptors (Figure 1F). HER2-overexpressing
cells have been shown to constitutively suppress PTEN activity
with increased PKB activity, and it has been shown that acute
Herceptin exposure decreased PKB phosphorylation through
PTEN activation [13]. We found that after 1 h of Herceptin
treatment, there was a decrease in PKB phosphorylation, and this
correlated with a decrease in HER3 phosphorylation in both
SKBR3 and BT474 cells (Figure 1F). Thus, acute Herceptin
treatment down-regulated HER2 receptors, resulting in a decrease
of HER3 phosphorylation and PKB phosphorylation.
HER2 Phosphorylation Is Maintained by Its Dimerisation
with Other HER Receptors through Ligand Release
The amplification of HER2 results in constitutive activation of
HER2 in a human mammary epithelial cell system [21]. We found
that although Herceptin down-regulated HER2 receptors, the
remaining cells had persistent and increased HER2 phosphoryla-
tion in both SKBR3 and BT474 cells (Figure 1A and 1D). Since
HER2 is the preferred dimerisation partner, we postulated that
HER2 phosphorylation was maintained by the other HER
receptors via their dimerisation with HER2. We proceeded to
show, using the streptavidine-biotin immunoprecipitation method
(see Materials and Methods), that acute Herceptin treatment
increased EGFR/HER2 dimerisation in BT474 cells (Figure 2A,
left two panels). This effect was specifically induced by Herceptin,
since 1 h of IgG treatment did not increase EGFR/HER2
dimerisation (data not shown). There was also an increase in
HER2/HER3 dimerisation in both SKBR3 and BT474 cells after
1 h of Herceptin treatment (Figure 2B, left upper and lower
panels). Furthermore, there was increased HER2 dimerisation
with the phosphorylated EGFR and HER3 receptors in BT474
cells treated with Herceptin (which was demonstrated using two
immunoprecipitation methods; see Materials and Methods)
(Figure 2B, middle two upper and lower panels). There was also
increased HER2 dimerisation with the phosphorylated HER4
receptor (Figure 2B, right upper and lower panels). Because of a
low level of HER4 expression in these cells, the quality of the
Western blot was not optimal using the streptavidin-biotin
immunoprecipitation method, despite repeated attempts
(Figure 2B, right upper panels). However, the quality of the blot
was better using the immunoprecipitation method with Herceptin
(Figure 2D, right lower panels).
We postulated that the increased dimerisation of EGFR, HER3,
and HER4 with HER2 was due to activation by their respective
ligands. We proceeded to assess the levels of endogenous ligands,
using heregulin (ligand for HER3 and HER4) and betacellulin
(ligand for EGFR and HER4) as examples. Herceptin-treated cells
were lysed, and endogenous ligand levels were detected using
ELISA. We found that Herceptin induced a statistically significant
up-regulation of heregulin and betacellulin (p=0.0152 and
p=0.0286, respectively) after 1 h of Herceptin treatment com-
pared to untreated cells in both SKBR3 and BT474 cells (data on
BT474 cells are shown in Figure 2C). There was also increased
secretion of these ligands in the conditioned medium of these cells
(Figure 2D). Thus, Herceptin increased the dimerisation of EGFR,
HER3, and HER4 with HER2 as a result of activation by their
ligands.
Herceptin Induces Phosphorylation of EGFR and HER4 As
Well As Reactivation of HER3 during Prolonged
Treatment
We showed that Herceptin induced an up-regulation of HER
ligands, including betacellulin and heregulin (Figure 2C and 2D).
This resulted in an increased phosphorylation of EGFR and
HER4 (Figure 2E) and an increase in their dimerisation with
HER2 (Figure 2A and 2B). Herceptin, however, decreased HER3
phosphorylation initially after 1 h of Herceptin treatment
(Figure 1F). We postulated that the increased heregulin release
(Figure 2C and 2D) with Herceptin treatment would have an effect
on HER3 phosphorylation. We showed that with prolonged
Herceptin treatment, HER3 phosphorylation was reactivated in
SKBR3 cells (Figure 2E). Reactivation of HER3 phosphorylation
also occurred in BT474 cells that became resistant to Herceptin
(Figure 2F). The total expression of HER3 and HER4 increased in
SKBR3 cells treated with Herceptin, but the total EGFR
expression decreased (Figure 2E). Thus, Herceptin induced ligand
activation of EGFR and HER4 as well as reactivation of HER3
phosphorylation during prolonged Herceptin treatment.
The Discordant Effects of Herceptin on ERK and PKB
Pathways
We analysed the effects of Herceptin on the downstream
signalling pathways in HER2-positive breast cancer cells. It was
found that the effects of acute Herceptin treatment on phosphor-
ylation of PKB and ERK1/2 were not concordant (Figures 1F,
2A, and 2E), in contrast to acute tyrosine kinase inhibitor (TKI)
treatment, which decreased both PKB and ERK phosphorylation
[17]. Acute Herceptin exposure increased ERK phosphorylation
(Figure 2A and 2E) but decreased PKB phosphorylation in BT474
and SKBR3 cells (Figure 1F).
Acute Herceptin exposure increased EGFR/HER2 and
HER2/HER4 dimerisation, correlating with an increase in
ERK phosphorylation (Figure 2A and 2E). In contrast, acute
Herceptin treatment decreased PKB phosphorylation (Figures 1F
and 2E); this decrease has been shown to be due to activation of
PTEN [13], correlating with a decrease in HER3 phosphorylation
(Figure 1F). With prolonged Herceptin treatment, reactivation of
PKB and HER3 occurred (Figure 2E). The increased ERK
phosphorylation was transient (Figure 2A and 2E), mimicking the
effect of exogenous ligand stimulation.
Therefore, Herceptin treatment decreased PKB phosphoryla-
tion because of a decrease in HER3 phosphorylation induced by
HER2 down-regulation. However, 1 h of Herceptin treatment
increased ERK phosphorylation as a result of ligand-dependent
EGFR and HER4 activation.
Exogenous HER Ligands Render Sensitive BT474 Cells
Resistant to Herceptin Treatment
To further show that HER ligands play a role in the acquired
resistance to Herceptin, we stimulated BT474 cells with 100 ng/ml
EGF, heregulin, or betacellulin while they were treated with 40 mg/
ml Herceptin. After 5 d, we assessed their cell viability. For
Herceptin treatment without exogenous ligands, there was a
decreased cell viability of BT474 cells, which was statistically
significant (p,0.001) (Figure 2G). However, when Herceptin
treatment was given in BT474 cells with concurrent stimulation of
exogenous HER ligands, the decrease in cell viability was reversed.
The reverse in cell viability in these conditions was statistically
significant compared to Herceptin treatment alone (p=0.0001 for
EGF, p=0.002 for heregulin, p=0.003 for betacellulin, respective-
ly, compared to Herceptin alone) (Figure 2G).
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Regulation of HER Ligands
We investigated the role of ADAM proteases since they mediate
shedding of pro-HER ligands including HB-EGF, epiregulin,
heregulin, and betacellulin [22]. As ADAM17 is one of the most
important ADAM proteases for HER ligands, we studied the role
of this ADAM protease in Herceptin treatment. SKBR3 cells were
transfected with small interfering RNA (siRNA) against ADAM17,
and the knockdown was validated by Western blot. There was a
decrease in both pro and active forms of ADAM17 in transfected
cells compared to the control (Figure 3A, left panels). We also
showed that heregulin production increased in response to acute
Herceptin exposure in cells transiently transfected with control
siRNA, but this production was inhibited by siRNA against
Figure 2. Herceptin induces the activation of HER receptors and their dimerisation with HER2 as a result of an up-regulation and
the release of HER ligands. (A) In the left two panels, BT474 cells were immunoprecipitated (IP) with either intracellular anti-EGFR or anti-HER2
antibody after 1 h of 40 mg/ml Herceptin treatment. Following the immunoprecipitation, the cell lysate was loaded unto an SDS gel, and a Western
blot analysis was performed. The membrane was probed with either anti-EGFR or anti-HER2 antibody, as illustrated. In the right panel, BT474 cells
treated for 1 h with 40 mg/ml Herceptin were lysed, and equal amounts were loaded on a gel. Membrane was probed for phosphorylated ERK and
actin. (B) In the left upper and lower panels, BT474 and SKBR3 cells were immunoprecipitated with biotinylated anti-HER2 antibody after the cells
were treated for 1 h with 40 mg/ml Herceptin. Following the immunoprecipitation, equal amounts of the cell lysates were loaded unto an SDS gel, a
Western blot analysis was performed, and the membrane was probed with anti-HER3 antibody. In the top right three panels, BT474 cells were
immunoprecipitated with biotinylated anti-HER2 antibody after 1 h of Herceptin treatment. Western blot analysis was done using antibodies that
recognised pEGFR, pHER3, or pHER4. In the lower right three panels, BT474 cells were treated with 40 mg/ml Herceptin for 1 h before the lysate was
immunoprecipitated using the anti-HER2 antibody Herceptin. After immunoprecipitation, lysate was loaded onto an SDS gel. A Western blot analysis
was performed, and the membrane was probed with anti-pEGFR, anti-pHER3, or anti-pHER4 antibodies. (C) BT474 cells were treated for 1 h with
40 mg/ml Herceptin, and the cells were lysed using Hepes buffer and homogenised before analysing the levels of heregulin and betacellulin by ELISA.
(D) In the left panel, serum-free medium of untreated and Herceptin-treated SKBR3 cells was immunoprecipitated for heregulin. A Western blot
analysis was then performed, and the membrane was probed for heregulin. In the right panel the same technique was used to look at betacellulin
levels in the medium of SKBR3 cells. (E) SKBR3 cells were lysed for Western blot analysis after pre-treatment with 40 mg/ml Herceptin. An equal
amount of protein was loaded in each lane. Four parallel SDS-PAGE gels were run, and the membranes were cut in different parts according to
molecular weight to analyse the total and phosphorylation levels of HER receptors, PKB, ERK, and actin using appropriate antibodies. (F) BT474 cells
were lysed after pre-treatment with 40 mg/ml Herceptin for 1 h, 4 h, or 8 mo. Equal amounts were loaded on an SDS gel, and membranes were
probed for phosphorylated HER3 and actin. (G) BT474 cells were treated for 5 d with either 40 mg/ml Herceptin alone or concurrent 40 mg/ml
Herceptin treatment with exogenous 100 ng/ml EGF, betacellulin (BTC), or heregulin (HRG) stimulation. Cells were then counted using a cell counter
to assess cell viability. For statistical analysis, untreated and Herceptin-treated samples were compared using the Mann-Whitney test. The Herceptin-
treated samples were then compared with samples treated with Herceptin and concurrent growth factor stimulation.
doi:10.1371/journal.pbio.1000563.g002
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Herceptin on the expression of ADAM17 protease. We demon-
strated that after treating the cells with Herceptin for 1 h,
ADAM17 protease mRNA was increased by 2.2-fold (n=4,
p=0.0008) (Figure 3B). To assess whether an increase in mRNA
production of ADAM17 was translated to protein, we proceeded
to assess ADAM17 protein level in response to Herceptin
treatment. We showed that Herceptin increased the protein levels
of ADAM17 in a dose-dependent manner after 1 h of treatment in
both BT474 (Figure 3C, left two panels) and SKBR3 (Figure 3C,
right two panels) cells. Furthermore, the increase of ADAM17
protease was shown to correlate with the suppression of PKB
phosphorylation by Herceptin (Figure 3C). As a control, we
treated MCF12F cells with Herceptin for comparison. Herceptin
did not cause significant pPKB inhibition nor affect ERK
phosphorylation in these cells after 1 h of treatment (Figure
S2C, right panels). In addition, Herceptin did not induce a
significant increase in ADAM17 level nor HER ligand levels
(heregulin and betacellulin) in the conditioned medium of the
normal epithelial breast cell line MCF12F treated with Herceptin
(Figure S2C).
In summary, we showed that ADAM17 is involved in the up-
regulation of heregulin in response to Herceptin treatment. We
found increased levels of mRNA and protein levels of ADAM17
protease in response to acute Herceptin exposure in HER2-
positive cells but not in normal epithelial MCF12F cells. The up-
regulation of ADAM17 was shown to correlate with the
suppression of PKB phosphorylation in HER2-overexpressing
cells.
Decrease in PKB Phosphorylation Initiates the Negative
Feedback Loop of ADAM17-Mediated HER Ligand
Release
We observed earlier that the up-regulation of ADAM17
correlated with the suppression of PKB phosphorylation by
Herceptin treatment, suggesting the existence of a negative PKB
feedback loop involving ADAM17 in acute Herceptin treatment.
We hypothesized that if there was a negative PKB feedback loop, a
PKB inhibitor should initiate the same response as Herceptin
treatment, inducing an up-regulation of HER ligands and
ADAM17 levels. To assess the role of a PKB feedback loop
induced by Herceptin treatment, we treated BT474 cells with a
Figure 3. Up-regulation of heregulin is mediated by ADAM17, and acute Herceptin treatment induces an increase in mRNA and
protein levels of ADAM17. (A) SKBR3 cells were transfected with siRNA against ADAM17 or a control sequence. The knockdown was validated by
Western blot for ADAM17 and actin (left panel). Knockdown cells were then treated with 40 mg/ml Herceptin for 1 h and lysed in Hepes buffer for
heregulin detection using ELISA (right panel). (B) SKBR3 cells were treated with 40 mg/ml Herceptin for 1 h, and ADAM17 mRNA levels were studied
by QPCR. The Mann-Whitney test was performed to determine statistical significance of the up-regulation of ADAM17 mRNA after Herceptin
treatment. (C) BT474 cells (left two panels) and SKBR3 cells (right two panels) were treated with an increasing dose of Herceptin over a period of 1 h.
Cell lysate was loaded onto an SDS gel, and a Western blot analysis was performed. The membrane was probed with anti-ADAM17 and anti-pPKB
antibodies. Quantification of three separate experiments is depicted in graphs for pPKB and ADAM17; representative blots are shown above the
graphs.
doi:10.1371/journal.pbio.1000563.g003
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decrease PKB phosphorylation via a mechanism different from
that of Herceptin.
Using the quantitative Meso Scale Discovery (MSD) method
(see Materials and Methods), we showed that the PKB inhibitor
decreased PKB phosphorylation after 1 h of treatment, which was
statistically significant in comparison to DMSO control treatment
(p,0.0001) (Figure 4A, left panel). Herceptin also decreased PKB
phosphorylation in comparison with untreated cells (p=0.03
compared to untreated) (Figure 4A, left panel). Neither PKB
inhibitor nor Herceptin decreased total PKB levels in comparison
to control cells treated with IgG or DMSO (Figure 4A, right
panel).
We also assessed the effects of the PKB inhibitor on PKB and
ERK phosphorylation in BT474 cells using Western blot. As
expected, 1 h of treatment with 2.5 mM PKB inhibitor, but not
DMSO, decreased PKB phosphorylation. However, it also
increased ERK phosphorylation (Figure 4B), just like acute
Herceptin treatment (Figure 2A and 2E). More importantly, the
decrease in PKB phosphorylation by the PKB inhibitor was also
associated with an increase in heregulin production (p=0.012)
(Figure 4C) and an up-regulation of ADAM17 mRNA levels
(p=0.016) (Figure 4D). Thus, the decrease in PKB phosphoryla-
tion by a PKB inhibitor initiated the same feedback loop as that
seen in Herceptin treatment, which reduces PKB phosphorylation
via a different mechanism.
Inhibition of ADAM17 Abrogates the PKB Negative
Feedback Loop, Resulting in Suppression of HER2
Phosphorylation
In order to further prove the existence of a PKB negative
feedback loop involving ADAM17 during Herceptin treatment, we
needed to demonstrate that we can abrogate the loop and suppress
HER2 phosphorylation by inhibiting ADAM17.
HER2-overexpressing cells express autocrine ligands, including
heregulin, resulting in HER2 activation and basal phosphoryla-
tion. We showed that 1 h of treatment with TAPI-1 (an ADAM17
and metalloprotease inhibitor) or with specific ADAM17 inhibitor
and ADAM10/17 inhibitor was able to inhibit basal HER2
phosphorylation in SKBR3 cells (Figure 5A). Whereas acute
Herceptin exposure increased HER2 phosphorylation in SKBR3
cells (Figure 1A), combination treatment with Herceptin and
TAPI-1 decreased HER2 phosphorylation (Figure 5A). We also
investigated the effect of the combination of Herceptin and TAPI-
Figure 4. Inhibiting PKB phosphorylation by a PKB inhibitor induces up-regulation of heregulin and ADAM17. (A) BT474 cells were
treated for 1 h with 40 mg/ml Herceptin (Herc), 2.5 mM PKB inhibitor (PKB inh), 40 mg/ml IgG control, or DMSO control at 37uC. After 1 h, cells were
lysed and analysed for total and phosphorylated PKB levels using MSD multiplex kits. (B) BT474 cell lysates were loaded on an SDS gel, and the
membranes were probed for phosphorylated ERK, PKB, and actin. (C) BT474 cells pre-treated with PKB inhibitor were lysed in Hepes buffer and
homogenised before analysing protein levels of heregulin using ELISA. (D) BT474 cells were treated with PKB inhibitor for 1 h, and ADAM17 mRNA
levels were studied by QPCR. Statistical significance was determined using the Mann-Whitney test.
doi:10.1371/journal.pbio.1000563.g004
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phosphorylation of HER2 in SKBR3 cells, as shown by a decrease
in the average lifetime of HER2-Cy3b with pHER2-Cy5 from
about 2.05 ns to 1.6 ns (Figure 5B). Acute Herceptin treatment did
not decrease HER2 phosphorylation (Figure 1A and 1C), but with
concurrent TAPI-1 inhibitor treatment there was suppression of
HER2 phosphorylation (an increase in the average lifetime)
(p=0.008) (Figure 5B).
To further prove the role of ADAM17 in the negative feedback
loop, we transiently transfected SKBR3 cells with siRNA against
ADAM17. We showed that Herceptin was unable to decrease
HER2 phoshorylation in control cells. However, in cells that were
transfected with specific siRNA against ADAM17, HER2 phos-
phorylation was decreased after Herceptin treatment (Figure 5C).
We proceeded to assess the effect of various ADAM17 inhibitors
on cell viability with or without concurrent Herceptin treatment.
We hypothesized that the combination of Herceptin with
ADAM17 inhibitors would exert greater inhibition than Herceptin
alone. We showed that combination of Herceptin with either
TAPI-1 or specific ADAM17 inhibitor exerted greater inhibition
of cell viability in BT474 cells after 2, 3, or 6 d of treatment
(Figure 5D).
Thus, our data prove that inhibition of ADAM17 is able to
abrogate the feedback loop that maintains HER2 phospshoryla-
tion during Herceptin treatment.
A panHER Inhibitor Abrogates the PKB Negative
Feedback Loop, and the Combined Treatment of a
panHER Inhibitor with Herceptin Is Synergistic in
Inhibiting Xenograft Tumour Growth
We demonstrated earlier that ADAM17 inhibitors were able to
abrogate the PKB negative feedback loop and inhibit HER2
phosphorylation during Herceptin treatment. Since an up-
regulation of ADAM17 and HER ligands resulted in activation
of all HER receptors, we hypothesized that a panHER inhibitor
should also be able to reverse the effect of the PKB negative
feedback loop induced by Herceptin treatment.
Figure 5. Combination of Herceptin with ADAM inhibitors decreases HER2 phosphorylation and is additive in cell viability
inhibition. (A) SKBR3 cells were treated with 100 mM ADAM17 inhibitor (inh), 100 mM ADAM10/17 inhibitor, 100 mM ADAM inhibitor TAPI-1, or a
combination of TAPI-1 and 40 mg/ml Herceptin (Herc) for 1 h. Cells were then lysed, and equal amounts of protein were loaded on an SDS gel.
Membrane was probed for phosphorylated HER2 and actin. (B) FRET experiments to assess HER2 phosphorylation in SKBR3 cells. The cells were
treated with 40 mg/ml Herceptin for 1 h with or without TAPI-1. The medians of the lifetimes were compared with the basal condition using the
Mann-Whitney test. (C) SKBR3 cells were transfected with siRNA against ADAM17 or a control sequence. Three days after transfection, cells were
treated with 40 mg/ml Hercpetin for 1 h. Lysates were loaded on an SDS gel. The membrane was probed for pHER2 and actin. (D) BT474 cells were
grown in 24-well plates and left to grow for at least 24 h before being treated for different durations with 40 mg/ml Herceptin, 10 mM TAPI-1, 10 mM
ADAM17 inhibitor, or a combination of ADAM inhibitors with Herceptin, as illustrated. The viable cells were counted using a cell counter.
doi:10.1371/journal.pbio.1000563.g005
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the activation of all HER receptors, could decrease HER2
phosphorylation and be synergistic in tumour growth inhibition
with Herceptin treatment. JNJ-26483327 is a potent multi-kinase
inhibitor against EGFR (half-maximal inhibitory concentration
[IC50]=9.6 nM), HER2 (IC50=18 nM), and HER4
(IC50=40.3 nM) [23] (Figure S4A). It is also known as a panHER
inhibitor since its IC50 against these receptors is comparable with
that of other panHER inhibitors [24]. We found that 1 h of
treatment with either 40 mg/ml Herceptin or 10 mM JNJ-
26483327 was not able to decrease HER2 phosphorylation in
SKBR3 cells (Figure 6A). However, the combination of Herceptin
treatment with either 5 mMo r1 0mM JNJ-26483327 for 1 h was
able to decrease HER2 phosphorylation in these cells (Figure 6A).
Furthermore, whereas Herceptin treatment alone increased
ADAM17 (p=0.011) and heregulin (p=0.008) mRNA levels,
neither JNJ-26483327 treatment nor the combined treatment of
Herceptin with JNJ-26483327 increased their levels compared to
the untreated cells (Figure 6B). Therefore, the combined treatment
of a panHER inhibitor with Herceptin could abrogate the PKB
feedback loop involving ADAM17 and heregulin. We also showed
that the combination of Herceptin and panHER inhibitor JNJ-
26483327 exerted greater inhibition of cell viability after 3, 6, or
8 d of treatment compared to Herceptin or JNJ-26483327 alone
(Figure 6C). We investigated whether a panHER inhibitor in
combination with an ADAM17 inhibitor without Herceptin
treatment could exert similar synergistic effect. However, JNJ-
26483327 with TAPI-1 exerted less cell viability inhibition than
Herceptin alone in both SKBR3 and BT474 cells (Figure S4C).
This may be because neither JNJ-26483327 alone nor JNJ-
26483327 with TAPI-1 could decrease pHER3 and pAKT after
1 h of treatment, in contrast to Herceptin or Herceptin with JNJ-
26483327 (Figure S4B).
To test the in vivo relevance of the interaction between a
panHER inhibitor and Herceptin, BT474 xenografts were treated
with an empty vehicle, Herceptin alone, the panHER inhibitor
JNJ-26483327 alone, or the combination of drugs for 21 d
(Figure 6D). As seen in Figure 6D, Herceptin alone or the
panHER inhibitor alone could only delay xenograft tumour
growth compared to vehicle treatment, but the combination of the
two drugs caused an almost complete inhibition of tumour growth
in these HER2-positive xenografts.
In summary, Herceptin in combination with a panHER
inhibitor was able to decrease HER2 phosphorylation and
abrogated the up-regulation of ADAM17 and heregulin in
response to Herceptin treatment. Whereas either a panHER
Figure 6. Combination of Herceptin with a panHER inhibitor abrogates the PKB feedback loop and is synergistic in inhibition of
xenograft tumour growth. (A) SKBR3 cells were treated for 1 h with 40 mg/ml Herceptin (Herc) alone, 10 mM panHER inhibitor JNJ-26483327
alone, or Herceptin with 1, 5, or 10 mM JNJ-26483327. Cell lysate was loaded onto an SDS gel, and a Western blot analysis was performed. Membranes
were blotted with antibodies recognising pHER2 and b-actin. (B) BT474 cells are treated with 40 mg/ml Herceptin, 5 mM JNJ-26483327, or a
combination of both drugs for 1 h. ADAM17 mRNA and heregulin mRNA levels were studied by QPCR. p-values were calculated using the Mann-
Whitney test comparing treated samples against untreated samples. (C) BT474 cells were grown in a 24-well plate and left to grow for at least 24 h
before being treated for different durations with 40 mg/ml Herceptin, 5 mM JNJ-26483327, or a combination of these drugs, as illustrated. The viable
cells were counted using a cell counter. (D) BT474 xenografts were treated with an empty vehicle, JNJ-26483327 (75 mg/kg twice a day orally [BID
p.o.]), Herceptin (10 mg/kg twice weekly intraperitonealy [i.p.]), or a combination of JNJ-26483327 with Herceptin treatment for 21 d and were
observed for a period of 120 d.
doi:10.1371/journal.pbio.1000563.g006
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tumour growth, the combination treatment was synergistic in
tumour inhibition.
Discussion
It was previously thought that Herceptin inhibits HER2
receptor tyrosine kinase activity, but recent studies have shown
that this is not the case [14,15]. The mechanisms whereby
Herceptin fails to decrease HER2 phosphorylation remain
unclear. Our results confirmed that Herceptin did not decrease
HER2 phosphorylation although it down-regulated HER2
receptors in HER2-positive SKBR3 and BT474 breast cell lines.
We showed that HER2 phosphorylation was maintained and
increased by the ligand-induced activation of EGFR, HER3, and
HER4 receptors, which preferentially dimerise with HER2. This is
consistent with reports that Herceptin does not prevent the
dimerisation of HER2 with other receptors [25].
It was previously demonstrated that primitive mammary stem
cells are enriched in vitro in non-adhering spherical colonies called
mammospheres [26]. These cells have stem-cell-like properties,
with the ability to undergo multi-lineage differentiation [26]. The
proportion of these stem cells in normal mammary epithelial cells
is increased by HER2 overexpression, as demonstrated by in vitro
mammosphere assays and the expression of the stem cell marker
ALDH [18]. One of the clinical benefits of Herceptin is thought to
be its ability to target the cancer stem cell population in HER2-
amplified tumours [19]. We confirmed in our study that Herceptin
decreased ALDH-positive stem cells after a prolonged treatment,
in correlation with a decrease in HER2 receptors. However, there
was significant heterogeneity in the inhibition of HER2 phos-
phorylation by Herceptin between different cells, especially during
the first week of treatment. Thus, Herceptin was able to decrease
HER2-mediated signalling in some of these cells, resulting in
decreased HER2 receptors and phosphorylation, but Herceptin
monotherapy could not eliminate all the stem cells. The surviving
cells had decreased HER2 receptors and fewer ALDH-positive
cells compared to untreated cells but had maintained HER2
phosphorylation via activation of other HER receptors as a result
of ADAM17-mediated ligand release.
HER3 is kinase-defective, and its phosphorylation depends on
other HER receptors. The effects of Herceptin on HER3
phosphorylation have been controversial. Yakes et al. [27] showed
that 1 h of Herceptin treatment induced a transient increase of
pHER3 in BT474 cells, whereas Junttila et al. [15] reported a
decrease of pHER3 with acute Herceptin treatment. We showed
that acute Herceptin treatment initially decreased HER3 phos-
phorylation. This decrease is thought to be due to HER2 down-
regulation, since loss of HER2 induced by siRNA decreased
pHER3 levels in HER2-positive breast cancer cells [20]. It is
possible that the difference in observed pHER3 is due to several
factors that are competing to affect pHER3 levels. The dominant
effect of acute Herceptin treatment is a decrease in HER2 levels,
but this is in competition with the increased HER3 phosphory-
lation as a result of increased ligand production induced by
Herceptin treatment. This would account for the subsequent
reactivation of HER3 with prolonged Herceptin treatment.
Furthermore, variable cell lines and experimental conditions, as
well as different treatment durations and doses of Herceptin used
by different investigators, may account for differences in pHER3
levels seen [15,27].
We found that Herceptin had a discordant effect on PKB and
ERK signalling. HER2-overexpressing cells have been shown to
activate Src with constitutively suppressed PTEN activity and
increased PKB activity [13,28]. Herceptin increased PTEN
membrane localisation and phosphatase activity by reducing
PTEN tyrosine phosphorylation via Src inhibition, leading to a
decreased PKB phosphorylation [13]. The decrease in PKB
activity is not due to PI3K inhibition, since there was no decreased
PI3K activity after Herceptin treatment [13]. However, acute
Herceptin activates ERK1/2 pathways, correlating with an
increase in EGFR and HER4 dimerisation with HER2. Since
EGFR, HER3, and HER4 have binding sites for Shc and Grb2
[29], their ligand-dependent activation would account for
increased activation of ERK by acute Herceptin treatment. The
sudden increase in ERK phosphorylation induced by Herceptin
treatment is very much similar to MAPK/ERK activation in cells
stimulated with exogenous HER ligands [30]. This observation
supports our data that Herceptin induces the up-regulation of
HER ligands through ADAM proteases.
Sergina et al. [31] showed that TKI treatment failed to suppress
HER3 phosphorylation for a sustained duration because of a
PKB-mediated feedback loop. However, they did not link the
PKB-mediated feedback loop with the HER ligands and ADAM
proteases. We have previously shown that reactivation of HER3
and PKB in response to TKI is due to HER ligand release [16].
We have now shown that acute Herceptin treatment decreases the
phosphorylation of HER3 and PKB, which in turn induces the
activation of a feedback loop involving HER ligands and ADAM
proteases. We postulated that Herceptin treatment initiated a
PKB-mediated negative feedback loop. If such a negative loop
exists, we predicted that an inhibitor that decreases PKB
phosphorylation should also induce the up-regulation of HER
ligands and ADAM17 protease. Indeed, we demonstrated that a
PKB inhibitor, which decreases PKB phosphorylation via a
mechanism different from that of Herceptin, could also initiate the
same feedback loop induced by Herceptin treatment. Thus, it is a
Herceptin-induced decrease in PKB phosphorylation that results
in the activation of a feedback loop involving ADAM proteases
and HER ligands. This PKB feedback loop activates the other
HER receptors and maintains HER2 phosphorylation, which is a
key to acquired resistance to Herceptin (Figure 7).
There have been several reports of positive and negative
feedback loops linking the complex cross talk of MAPK and PI3K
signalling pathways with scaffolding protein Grb2-associated
binders 1 and 2 (Gab1 and Gab2) [30,32]. mTOR inhibition
has also been shown to lead to MAPK activation through a PI3K-
dependent feedback loop in human cancer [33]. The exact
mechanism of how these feedback loops link to each other is likely
to be very complex. It is likely that FoxO proteins, which are
downstream targets of PKB, are central players in this PKB
feedback loop [34]. The phosphorylation of FoxO transcription
factors by PKB promotes the cytoplasmic sequestration of these
transcription factors, including FoxO3a [34]. It is likely that FoxO
transcriptional factors can modify Akt/PKB phosphorylation
indirectly by modifying the expression of kinases or phosphatases
[35]. It is also possible that FoxO proteins regulate the
transcription of ADAM17, since PKB inhibition increases mRNA
production of ADAM17. The interactions of FoxO transcriptional
factors with ADAM proteases and phosphatase, as well as how
they affect the phosphorylation and dephosphorylation of PKB
and HER receptors, are likely to be very complicated. The
mechanisms are currently being investigated in our lab.
Our xenograft experiment showed that neither panHER
inhibitor nor Herceptin treatment alone was adequate to control
tumour growth in a HER2-oncogene-driven tumour. In HER2-
positive breast cancer, the underlying problem is HER2
overexpression, which results in increased HER2-related signal-
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PLoS Biology | www.plosbiology.org 10 December 2010 | Volume 8 | Issue 12 | e1000563Figure 7. The proposed model of acquired resistance to Herceptin in HER2-overexpressing breast cancer. In the top diagram, HER2
overexpression (both homodimers and heterodimers) leads to constitutive activation of EGFR and HER2 with MAPK activation [21]. These cells have
also been shown to have activated Src with constitutively suppressed PTEN activity and increased PKB activity [13,28]. In the middle diagram,
Herceptin increases PTEN membrane localisation and PTEN activation in HER2-overexpressing cells, resulting in suppression of PKB phosphorylation
[13]. This inhibition induces the PKB negative feedback loop, triggering the production and release of HER ligands through ADAM17 protease. In the
Herceptin Induces a PKB Negative Feedback Loop
PLoS Biology | www.plosbiology.org 11 December 2010 | Volume 8 | Issue 12 | e1000563ling. Herceptin is able to down-regulate HER2 receptors, whereas
TKI-like lapatinib induces HER2 accumulation at the cell surface
[14]. We have shown that a panHER inhibitor with TAPI-1
(ADAM17 inhibitor) resulted in less inhibition of cell viability than
Herceptin alone in both SKBR3 and BT474 cells. This confirms
that TKI treatment without Herceptin is not as effective as
treatment with either Herceptin or Herceptin with TKI in HER2-
positive breast cancer cells. However, the combination of
Herceptin with a panHER inhibitor, which inhibits the activation
of all HER receptors, was able to abrogate the feedback loop
during Herceptin treatment and was synergistic in tumour
inhibition in a HER2-positive BT474 xenograft model. Our data
would support the rationale of combining a panHER inhibitor
with Herceptin treatment in patients with HER2-positive breast
cancer. Our results would also explain why pertuzumab and
Herceptin are synergistic in tumour inhibition in breast cancer
cells and xenograft models [20]. Furthermore, it would account for
the effectiveness of a combination treatment of pertuzumab with
Herceptin in some patients whose disease progressed while on
Herceptin alone [36].
Our results demonstrate why it is inadequate to consider
individual HER receptors alone for anti-HER therapies as these
receptors are intrinsically linked together with a close network of
feedback loop(s). We have demonstrated that a PKB feedback loop
is activated upon Herceptin treatment, resulting in the activation
of all HER receptors and maintenance of HER2 phosphorylation.
We have not attempted to look at all the positive and negative
feedback loops linking MAPK and PI3K [30,32]. It is likely that
more feedback loops are involved in the acquired resistance to
Herceptin. Future research should identify the exact candidates,
other than ADAM17 and HER ligands, involved in the feedback
loops. Such candidates are best identified through a systems
biology approach, which may help to further dissect the
mechanisms of acquired resistance to Herceptin in HER2-
overexpressing tumours and to improve the survival for patients
with this type of tumour.
Materials and Methods
Materials and Cell Lines
SKBR3 and BT474 cells were obtained from cell services at
Cancer Research UK (Lincoln’s Inn Fields laboratory). The
human cell lines BT474 and SKBR3 are HER2-overexpressing
breast cancer cell lines. SKBR3 cells were cultured in Dulbecco’s
Modified Eagle Medium (DMEM) supplemented with 10% fetal
bovine serum and the antibiotic penicillin-streptomycin. BT474
cells were cultured in RMPI supplemented with 10% fetal bovine
serum and the antibiotics penicillin-streptomycin. For these cells,
10 mg/ml insulin was added to the medium when cells were split
or medium was refreshed. Normal breast epithelial MCF12F cells
were purchased from the ATCC and cultured in a 1:1 mixture of
DMEM and Ham’s F12 medium supplemented with 20 ng/ml
EGF, 100 ng/ml cholera toxin, 0.001 mg/ml insulin, 500 ng/ml
hydrocortisone, and 5% horse serum.
Anti-HER2 (recognising the intracellular residues), anti-phos-
pho-HER2 (Tyr1221/1222), anti-phospho-HER3 (Tyr1289), anti-
HER4 (recognising the intracellular residues near the carboxyl-
terminus of human HER4), and anti-phospho HER4 (Tyr1284)
antibodies were obtained from Cell Signalling Technology. The
polyclonal anti-phospho-EGFR (Thr992) was obtained from
Invitrogen. F4-IgG1 mouse monoclonal antibody (against the
EGFR cytoplasmic domain) was obtained from the monoclonal
antibody laboratory of Cancer Research UK (Lincoln’s Inn Fields
laboratory). Antibodies recognising PKB, phospho-PKB (Ser473),
p44/42 MAP kinase (Erk1/Erk2), and phospho-Erk1/Erk2
(Thr202/Tyr204) were from Cell Signalling Technology. Anti-
ADAM17 was purchased from Abcam. The secondary antibodies,
goat anti-mouse IgG and goat anti-rabbit IgG, were purchased
from GE Healthcare. The mono-conjugated fluorophores Cy3B
and Cy5 were from GE Healthcare. PKB inhibitor (Akt inhibitor
VIII, isozyme-selective, Akti-1/2) was obtained from Calbiochem.
Herceptin was initially a gift from Roche, but subsequent supply
was obtained from the pharmacy department of Oxford Radcliffe
Hospitals, National Health Services Trust. Human IgG control
was purchased from R&D Systems. EGF, heregulin, and
betacellulin were purchased from Sigma Aldrich. ADAM and
metalloprotease inhibitor (TAPI-1) was purchased from Calbio-
chem. Incyte kindly provided ADAM17 inhibitor INCB4298 and
ADAM10/17 inhibitor INCB3619. Janssen (Johnson & Johnson)
kindly provided panHER inhibitor JNJ-26483327.
Western Blotting
For Western blotting confluent six-well plates of cells were
placed on ice and washed with PBS. Cells were scraped off the
plates and incubated for 10 min in lysis buffer (10 mM EDTA,
20 mM Tris [pH 7.5], 150 mM NaCl, 10 mM Na2P2O7, and
100 mM NaF with 1% Triton and protease inhibitor cocktail
[Roche]). Samples were centrifuged at 4uC to remove the
insoluble cell pellets, and a protein assay was performed to check
protein quantity. Equal amounts of protein sample were prepared
in 46SDS with 10% beta-mercaptoethanol and boiled for 10 min
at 95uC. Then samples were loaded on a NuPage 4%–12% gel
(Invitrogen) and run at 130 V. The proteins were semi-dry-
transferred to a membrane for 2 h at 12 V. The membrane was
blocked in 3% BSA in PBS-Tween (0.2%) for a minimum of 1 h.
Then the blot was incubated with primary antibody in the same
solution for 3 h at room temperature. The membrane was washed
four times with 1% milk in PBS-Tween (0.2%) before secondary
antibody was added in 5% milk in PBS-Tween (0.2%). The
membrane was incubated at room temperature for 1 h before it
was washed four times again with 1% milk in PBS-Tween (0.2%).
Antibodies were visualised with an enhanced chemiluminescent
(ECL) system (GE Healthcare).
Immunoprecipitation
BT474 and SKBR3 cells were grown to near confluency before
they were lysed as described above. The cell lysate was centrifuged
for 10 min at maximum speed before transferring the supernatant
to a new reaction vial. A protein assay was performed to check
protein quantity, and equal amounts of protein were used for
immunoprecipitation. In order to look at the interaction between
HER2 and other HER receptors after Herceptin treatment, we
needed a technique that would specifically pull down our protein
of interest. We could not use magnetic protein G beads because
they would bind Herceptin as well as our receptor-specific
antibody (data not shown). Therefore, streptavidin-coated mag-
netic beads (Bio-Nobile) were absorbed with biotin-conjugated
HER antibodies (1:100) (conjugated using kit from Innova
Biosciences) for 1 h, as illustrated in the figures. After the bead-
antibody complex was washed with PBS-Tween (0.2%), it was
bottom diagram, Herceptin down-regulates HER2 receptors, but the up-regulation of HER ligands causes activation of EGFR, HER3, and HER4 and
their dimerisation with HER2, resulting in the maintenance of HER2 phosphorylation, with increased activation of PKB and MAPK pathways.
doi:10.1371/journal.pbio.1000563.g007
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complex was thoroughly washed with PBS-Tween and transferred
to a new reaction vial. Wash buffer was taken off and 50 mlo f4 6
SDS with 10% beta-mercaptoethanol was added to the beads.
Samples were boiled for 10 min at 95uC to elude protein off the
beads. Twenty microlitres was loaded per lane in a SDS gel for
Western blot analysis, as described above. For further confirma-
tion, we also used protein G beads labelled with Herceptin (anti-
HER2) to pull down HER2, and looked at the levels of
phosphorylated HER receptors.
Cell Viability Experiments
SKBR3 and BT474 cells were grown in 24-well plates after
seeding approximately 20,000 cells per well. The cells were grown
for at least 24 h before treatment with 40 mg/ml Herceptin, 5 mM
JNJ-26483327, 10 mM TAPI-1, 10 mM ADAM17 inhibitor, or a
combination of these drugs for different durations, as illustrated in
the figures. For the exogenous ligand experiments, 100 ng/ml
EGF, heregulin, or betacellulin was added to the cells in addition
to Herceptin (40 mg/ml) for a total of 5 d in BT474 cells. On the
day of the experiment, the cells were trypsinized and diluted with
PBS. The viable cells were counted using a cell counter.
Transient Transfection
For all transient transfections, the cells were plated in 10-cm
2
dishes (50% confluent) in medium and given the opportunity to
settle overnight. The next day, medium was replaced by 7 ml of
fresh normal medium. Transfection mix containing 10 nM siRNA
in 300 ml of OptiMEM (Invitrogen) was incubated with 15 mlo f
NeoFX (Ambion) in 300 ml of OptiMEM for 15 min at room
temperature. This mix was added drop-wise to the cells, and cells
were placed back into the incubator. After 24 h, transfected cells
were re-plated into six-well plates for further experiments.
Validated siRNAs were obtained from Ambion.
Real-Time Quantitative PCR Analysis
Cells treated with Herceptin (40 mg/ml), PKB inhibitor
(2.5 mM), or panHER inhibitor JNJ-26483327 (5 mM) were
analysed for mRNA levels of ADAM17 and heregulin. RNA
was purified from cells using the Aurum Total RNA mini kit (Bio-
Rad) according to manufacturer’s instructions. RNA purity and
quantity were determined using Nanodrop (Nanodrop Technol-
ogies). For synthesis of the cDNA, a high-capacity cDNA reverse
transcription kit was used (Qiagen).
Quantitative PCR (QPCR) reactions were performed using the
following primers, together with FAM-labelled probes from the
Universal ProbeLibrary (Roche) or Sybergeen: Beta-actin primers,
59-ATTGGCAATGAGCGGTTC-39 and 59-GGATGCCACA-
GGACTCCAT-39, and universal probe 11; heregulin-b1 primers,
59- CTTGTGGTCGGCATCATGT-39 and 59-CAGCTTTTT-
CCGCTGTTTCT-93, and probe 49; ADAM17 primers, 59-
CCTTTCTGCGAGAGGGAAC-39 and 59- CACCTTGCAG-
GAGTTGTCAG-39 and probe 78.
cDNA samples were assayed in triplicate using a detection
system (Chromo4; GRI), and gene expression levels for each
individual sample were normalised relative to Beta-actin. Levels of
mRNA in untreated samples were set to 1.
Quantification of HER Ligand Levels by
Immunoprecipitation in Medium
We used immunoprecipitation to look at the levels of ligands
(betacellulin and heregulin) in the media of untreated or
Herceptin-treated cells. Cells were treated with Herceptin in
serum-free medium for 1 h. The medium was then collected and
incubated with magnetic protein G beads (Invitrogen) linked to
antibodies for heregulin or betacellulin for at least 1 h. The
samples were prepared for Western blot analysis as described
above.
Quantification of Ligand Levels by ELISA
Cells treated with Herceptin (40 mg/ml) or PKB inhibitor
(2.5 mM) were analysed for HER ligands. Levels of the HER
ligands betacellulin and heregulin were measured in cell lysate
using ELISA (R&D Systems). Cells were lysed in 20 mM Hepes
buffer containing 1.5 mM EDTA and protease inhibitor (Roche).
Cells were then scraped off and homogenised by putting the lysate
through a syringe with needle. After spinning the lysate down, the
supernatant was used for ELISA analysis.
To detect heregulin or betacellulin, the R&D Systems ELISA
kits were used as the protocol prescribes. Briefly, the ELISA plate
was coated overnight with coating buffer. After blocking the plate
for 2 h, 100-ml samples and standards were loaded and the plate
was kept at room temperature for 2 h. Samples were washed and
incubated with detection antibody for 2 h, then washed and
incubated with streptavidin labelled with horseradish peroxidase
for 20 min. With the use of a substrate solution that reacts with
horseradish peroxidase, the levels of ligands could be detected.
After 20 min, the reaction was stopped using stop solution, and
absorption was measured using an ELISA reader.
Quantification of Phosphorylated PKB and PKB Levels by
MSD
BT474 cells were plated on a six-well plate and left to settle
overnight. The next day, the cells were treated for 1 h with 40 mg/
ml Herceptin or 2.5 mM PKB inhibitor at 37uC. After 1 h, the
cells were lysed in a lysis buffer provided by MSD. The assay was
then performed following manufacturer’s protocol. In brief, MSD
provided the plates pre-coated with pPKB (Ser473) and PKB
spots. Multiple spots could be placed in one well of a 96-well plate,
making it possible to look at several proteins in one sample. The
plates provided were blocked for 1 h with 3% BSA at room
temperature. The plates were then washed three times with wash
buffer before 25 ml (20 mg) of sample was loaded onto the plates (in
duplicate). After incubation for 2 h at room temperature, the
plates were washed again, and 25 ml of detection antibody in 1%
BSA was added. After 1 h of incubation, 150 ml of read buffer was
added, and the plate was analyzed using a SECTOR imager
(MSD).
Fo ¨rster Resonance Energy Transfer
FRET experiments were performed as described previously
[16,17]. In short, 30,000 cells were seeded onto cover slips and left
to attach overnight. The next day, the cells were treated with
40 mg/ml Herceptin or the ADAM inhibitor TAPI-1 or the
combination of these drugs (for different durations as illustrated) in
the medium at 37uC. The medium was washed off with PBS, and
the cells were fixed with 4% paraformaldehyde (Pierce) in PBS for
10 min at room temperature. The cells were then permeabilized
with 0.2% Triton X-100 (T8532, Sigma-Aldrich) in PBS for 5 min
at room temperature before being treated for 10 min with 1 mg/
mg sodium borohydrate (Sigma-Aldrich) in PBS to quench the
background fluorescence. The cells were washed twice with PBS
between steps. Following the above steps, the cells were treated for
1 h with in 1% BSA (Sigma-Aldrich) in PBS at room temperature
to block unspecific binding of the antibodies. After that, antibodies
conjugated to the fluorescent dyes Cy3b or Cy5 were added to the
Herceptin Induces a PKB Negative Feedback Loop
PLoS Biology | www.plosbiology.org 13 December 2010 | Volume 8 | Issue 12 | e1000563samples sequentially starting with the Cy3b-conjugated antibody.
Cells were washed twice with PBS and twice with sterile water,
after which they were mounted onto a microscope slide using
Fluoromount-G (Southern Biotech). All images were taken using a
Zeiss Plan-APOCHROMAT 6100/1.4 NA phase three-oil
objective. Images were recorded at a modulation frequency of
80 MHz. The donor (Cy3b) was excited using the 514-nm line of
an argon/krypton laser, and the resultant fluorescence was
separated using a combination of dichroic beam splitter (Q565
LP, Chroma Technology) and narrow band emitter filter (BP 610/
75, Lys and Optik).
ALDH Assay
To detect ALDH activity in cells, we used the ALDEFLUOR
kit from Aldagen. The manufacturer’s protocol was followed
carefully. In brief, cells were trypsinized and, per treatment
protocol, 1610
6 cells were taken up into 1 ml of assay buffer
provided in the kit. This tube was the sample tube. To a separate
control tube, 5 ml of DEAB solution was added. ALDEFLUOR
substrate (5 ml) was added to the sample tube, and immediately
after mixing, 500 ml of the sample solution was transferred to the
control tube with DEAB. The procedure was repeated for all
samples. Both control and sample tubes were then placed at 37uC
for 45 min. After the cells were spun down for 5 min at 250 g, they
were taken up in new assay buffer and analyzed using a FACS
Cyan. Control samples were used to set a gate for ALDH
positivity, after which the test sample was analysed.
Statistical Analysis
The Mann-Whitney test was used to compare the medians of
the protein levels of heregulin and betacellulin as well as mRNA
levels of heregulin and ADAM17 between the untreated samples
and those treated with drugs. For each figure, at least three
experiments were done, and both technical and biological
replicates were used in the calculation, using a confidence interval
of 95%. Data were analysed against the untreated samples unless
otherwise stated.
Xenograft Experiment
Cell line. The human BT474 breast tumour cell line was
derived from a 60-y-old female Caucasian patient, and supplied by
OncoDesign. Cells were cultured at 37uC in a humidified
atmosphere (5% CO2, 95% air), in DMEM supplemented with
2 mM L-glutamine, 50 mg/ml gentamicin, 1 mM sodium
pyruvate, 1.5 g/l sodium bicarbonate, 4 mg/ml insulin, and
10% fetal bovine serum. Cells were maintained as monolayer
cultures, being passaged once weekly at 1610
7 cells per T175 flask
using the following procedure. Briefly, cells were washed with PBS,
before the addition of trypsin-EDTA to the culture flasks. After
detachment of cells the trypsin-EDTA was inactivated by addition
of complete medium. The cell suspension was then transferred to a
50-ml Falcon tube and centrifuged for 3 min at 1,200 rpm. The
medium was aspirated, with the cells being resuspended in an
appropriate volume of complete medium. The cells were counted
in a hemocytometer, and their viability was assessed by 0.25%
trypan blue exclusion. An appropriate volume of cell suspension
was then added to either a new T175 culture flask(s) or a roller
bottle containing fresh medium. For a large scale-up growth of
BT474 breast tumour cells, an appropriate number of triplet flasks
were seeded with 20610
6 cells 1 wk prior to inoculation of mice.
The medium was changed twice during this period, with the last
change being the day prior to cell injection. Cells were collected as
described above, with the exception that after centrifugation, the
cells were resuspended in cold (4uC) serum-free medium.
Study design. Human BT474 breast tumour cells were
injected directly into the inguinal region of the male NMRI
Nude mice (1610
7 cells/200 ml/animal) on day 0. On day 25,
when the tumour volume had reached an approximate average of
200 mm
3, mice were randomized according to tumour volume,
with ten mice per treatment group. Mice were then treated twice
daily with either vehicle (30% Captisol) or vehicle containing JNJ-
26483327 (75 mg/kg twice daily) by gavage (p.o.) for 21 d.
Alternatively, mice were treated twice weekly with either vehicle
(0.9% [w/v] NaCl) or a vehicle containing Herceptin (10 mg/kg)
by intraperitoneal injection administered in a volume of 10 ml/kg
body weight, for three cycles (i.e., 21 d). Another group received
combined doses of both agents. Tumour size and body weights
were measured twice weekly, with mice monitored daily for
clinical signs of toxicity for the duration of the treatment. Clinical
signs of toxicity included (but were not limited to) persistent
anorexia or dehydration, morbidity, lethargy, hypothermia, and/
or laboured respiration (according to the United Kingdom
Coordinating Committee on Cancer Research guidelines for the
welfare of animals in experimental neoplasia).
Data analysis. For each individual animal, body weight and
tumour size (using the commonly accepted formula: tumour
volume [mm
3]=a6b
2/2, where a represents the length, and b the
width of the tumour as determined by caliper measurements) were
monitored twice weekly throughout the study. A sustained body
weight loss greater than 15% of the initial body weight was
considered as clinical toxicity, with the animal removed from the
study and sacrificed. Time course of tumour growth was expressed
as median values, or normalised to initial tumour volume on the
day treatment started and expressed as mean 6 standard error of
the mean (eight animals per group). For pre-established tumours,
relative tumour volumes were calculated for each mouse (treated
tumour volume/tumour volume on day 0) and expressed as mean
6 standard error of the mean for each treatment group. Twenty-
four hours after their last treatment, animals were sacrificed, and
tumours were excised and weighed. Anti-tumour effect of
compound versus control was determined and represented by a
bar chart of median values 625/75 and 10/90 percentiles.
Statistical significance was indicated by one-sided p-values from
the Wilcoxon Mann-Whitney analysis (Wilcoxon rank sum test),
and p,0.05 was considered as statistically significant. Treatment/
control ratios were calculated based on final relative tumour
volumes, using the National Cancer Institute criteria.
Supporting Information
Figure S1 ALDH activity after treatment with Hercep-
tin. SKBR3 cells were treated with 40 mg/ml Herceptin for 2, 4,
or 6 d and were then analyzed for percentage of stem cells using
the ALDH assay. The experiment was repeated three times, and
the average percentage of cells positive for ALDH is depicted in a
graph. FACS plots of untreated SKBR3 cells and SKBR3 cells
treated with Herceptin for 6 d are depicted. On the left, the
control samples are shown, where the ALDH reaction is blocked
using DEAB. Negative cells are gated (R2). Using this gate on the
right figures, the percentage of ALDH-negative cells can be found.
Cells that fall outside of this gate are ALDH positive.
Found at: doi:10.1371/journal.pbio.1000563.s001 (1.31 MB TIF)
Figure S2 Control experiments. (A) In this experiment,
MCF12F cells were incubated with either the donor alone (HER2-
Cy3b) or donor and acceptor (HER2-Cy3b+pHER2-Cy5), to
assess HER2 phosphorylation by FRET after being pre-treated
with different durations of 40 mg/ml Herceptin as illustrated. (B)
Western blot experiment using the medium from the SKBR3 cells
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40 mg/ml Herceptin that was kept in an incubator for up to 10 d.
The medium was denatured with SDS-PAGE and boiled for
10 min, and 40 ml of 40 mg/ml Herceptin was loaded in each lane
of the SDS-PAGE. The membrane was probed with monoclonal
anti-human immunoglobulin antibody that recognises the Fc
component of Herceptin. (C) MCF12F cells were treated with
10 mg/ml Herceptin for 1 h in serum-free medium. The medium
was analysed for heregulin (left, top panel) and betacellulin (left,
bottom panel) using immunoprecipitation. Cells were lysed and
analysed by Western blot for ADAM17, pPKB, PKB, pERK,
ERK, and actin (right panels).
Found at: doi:10.1371/journal.pbio.1000563.s002 (1.14 MB TIF)
Figure S3 Chronic treatment with Herceptin induces its
resistance and decreases ALDH activity in BT474 cells.
(A) BT474 cells were treated with 40 mg/ml Herceptin for 3 or
6 d. The cells were trypsinized and counted using a cell counter.
In the middle panel, BT474 cells and BT474 cells cultured with
40 mg/ml Herceptin for over 8 mo (Herceptin-resistant BT474
cells) were treated for 6 d with 0, 20, or 40 mg/ml Herceptin. The
cells were then trypsinized and counted using a cell counter. (B)
Untreated BT474 cells and long-term Herceptin-treated BT474
cells (40 mg/ml Herceptin for over 8 mo) were analyzed using the
ALDH assay. The average percentage of cells positive for ALDH
is depicted in a graph.
Found at: doi:10.1371/journal.pbio.1000563.s003 (0.26 MB TIF)
Figure S4 Kinase inhibition assay of JNJ-26483327 and
its effect in combination with Herceptin or ADAM17
inhibitor TAPI-1. (A) JNJ-26483327 (a multi-kinase inhibitor
and also known as a panHER inhibitor) was tested against a panel
of around 230 wild-type and mutant kinases at a concentration of
1 mM and an ATP concentration of 10 mM. Dose response tests
were carried out for all those that showed greater than 50%
inhibition. (B) SKBR3 cells were treated with 40 mg/ml Herceptin,
10 mM TAPI-1, a combination of TAPI-1 and Herceptin, 5 mM
panHER inhibitor (JNJ-26483327), or a combination of the
panHER inhibitor with TAPI-1. Western blot analysis was
performed for pHER2, pHER3, pPKB, PKB, pERK, and ERK.
(C) SKBR3 cells were treated with 40 mg/ml Herceptin, 10 mM
TAPI-1, 5 mM JNJ-26483327, a combination of JNJ-26483327
with TAPI-1, or a combination of TAPI-1, JNJ-26483327, and
Herceptin for a period of 6 d. The cells were then trypsinized and
counted using a cell counter.
Found at: doi:10.1371/journal.pbio.1000563.s004 (1.00 MB TIF)
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